Articles tagged with Cancer Patients
African-American women with ER+ breast cancer experience poorer outcomes due to increased activation of the unfolded protein response (UPR) pathway, reducing sensitivity to tamoxifen treatment. Strategies targeting this pathway could improve therapy effectiveness.
Dr. Mario Capecchi has made significant contributions to cancer research through his development of gene targeting technology, revolutionizing the study of cancer genes and mechanisms of cancer development. He will be presented with the AACR Award for Lifetime Achievement in Cancer Research at the 2015 Annual Meeting.
A research team led by Charles Sawyers and Howard Scher discovered novel antiandrogen enzalutamide, which extended survival among patients with metastatic castration-resistant prostate cancer. The AACR Team Science Award recognizes the team's innovative work in advancing cancer research.
Dr. Carl June is being recognized for his contributions to cancer immunology, particularly his development of chimeric antigen receptor (CAR) T-cell therapy. His work has enhanced the promise of cancer immunotherapy and led to significant breakthroughs in treating leukemia.
David Baltimore is being recognized for his groundbreaking discoveries in immunology, virology, and cancer research. He will present a lecture on microRNAs, leukemia, and hematopoietic stem cells homeostasis at the AACR Annual Meeting 2015.
Margaret Foti, AACR CEO, will receive the Children's Champion Award for her outstanding pediatric cancer advocacy efforts. The award recognizes her leadership in advancing research and treatment for children with cancer.
A recent study by the Journal of the American College of Surgeons found that socioeconomic factors such as income level, education, and hospital type significantly impact lung cancer patients' odds of death within 30 days after surgery. Patients from lower-income households were 25% more likely to die than those in higher-income areas.
A new scoring method called MATH measures genetic variability among cancer cells within tumors from patients with head and neck cancer. High MATH scores correspond to tumors with many differences among gene mutations present in different cancer cells, correlating with lower patient survival.
James Allison, a renowned immunologist, has been recognized for his pioneering discovery that blocking CTLA-4 improves antitumor immune responses. His work led to the development of ipilimumab, an immune checkpoint inhibitor that transformed melanoma treatment.
A study by Dartmouth-Hitchcock's Camilo Fadul and colleagues found no correlation between regulatory T cells (Tregs) and patient survival in glioblastoma. The researchers used a novel epigenetic quantitative analysis methodology to quantify lymphocyte populations, including Tregs, in tumor tissue and peripheral blood.
James P. Allison is being acknowledged for his discovery that blocking CTLA-4 signaling improves antitumor immune responses, leading to the development of ipilimumab, a cancer immunotherapeutic. His research has transformed the lives of patients with melanoma and offers hope for other forms of cancer.
Dr. Coffey will receive the award for his pioneering work on prostate cancer, nuclear matrix, and mentoring of young researchers. He is also recognized for his outstanding leadership skills and advocacy for sustained funding for cancer research.
A new clinical trial found that early initiation of palliative care significantly improved one-year survival rates among patients with late-stage cancer. Additionally, caregivers experienced reduced depression and stress levels when interventions started earlier in the patient's life.
Researchers at Queen's University Belfast have launched a revolutionary personalized treatment program to improve bowel cancer survival rates. The S-CORT Consortium will employ state-of-the-art techniques to define the genetic make-up of bowel cancer cells, collected from over 2,000 patients, and develop personalized care plans.
Recent studies in Cancer Cell and Trends in Immunology review the intricate relationship between the immune system and cancer. Research has shown that harnessing anti-tumor immunity can be a promising approach to treating various cancers.
Researchers James P. Allison and Padmanee Sharma argue that combining targeted therapies with immunotherapy could be key to developing curative treatments for various cancer types, building on promising results from clinical trials.
Women with ductal carcinoma in situ breast cancer underwent axillary lymph node evaluation at high rates, defying guidelines. The study found that 17.7% of women undergoing breast-conserving surgery and 63% of those who had mastectomy underwent axillary evaluation.
A Yale study found that one in five Medicare patients with melanoma experience significant delays in getting surgery, affecting their psychological well-being and healthcare quality. The study analyzed data from over 32,000 Medicare patients and revealed that 22% waited longer than 1.5 months for treatment.
A study by Professor Rama Khokha found that genetically modified mice without TIMP1 and TIMP3 experienced youthful breast tissue, with stem cells remaining functional throughout their lifetime. The results challenge the assumption that large numbers of stem cells increase cancer risk.
Dr. Owen Witte, a pioneer in human leukemias and immune disorders, received the AACR G.H.A. Clowes Memorial Award for his groundbreaking work on tyrosine kinases as drug targets. His discoveries have led to multiple approved targeted therapies, transforming patient outcomes.
A third of breast cancer patients report strong desire for genetic testing but many do not receive relevant discussions with healthcare professionals. This study highlights the unmet need for addressing genetic risk in these patients.
Therapeutic anti-cancer vaccines have been associated with a statistically significant increase in patient survival, but rarely have a noticeable effect on tumor growth. The study suggests that overall survival, rather than progression-free survival, should be the gold standard for evaluating cancer vaccine efficacy.
Breast cancer cells' growth is inhibited by a combination of estradiol and tumor necrosis factor alpha, improving clinical outcomes for some subtypes. The altered gene expression patterns can be used as biomarkers to determine risk and therapy response.
Patients with stage IV cancer prioritize pain management, home deaths, and quality of healthcare over life extension, while caregivers are willing to pay more for these services. The study suggests that patients' preferences should be directly elicited during treatment decision-making.
A clinical trial is enrolling children and adults with graft-versus-host-disease using their own immune cells to target inflammation and reduce organ damage. The personalized cells are derived from the patient's own bone marrow, making them more likely to be effective.
A new review emphasizes the need to decipher immune response dynamics to enhance cancer immunotherapy. Researchers suggest developing combination therapies and biomarker panels to increase treatment impact, as single biomarkers are unlikely to predict patient responses.
A Cancer Research UK review found that older people, women, and less affluent individuals are at a higher risk of emergency cancer diagnoses. The study also revealed that emergency-diagnosed cancers tend to have poorer survival rates compared to those diagnosed through other routes.
A new study found that patients with lower vitamin D levels before treatment for follicular lymphoma have a worse prognosis and are more likely to succumb to the disease or face relapse earlier. Vitamin D deficiency may represent a modifiable risk factor for this type of cancer.
Dr. Lewis C. Cantley is being recognized for his groundbreaking work in discovering the phosphoinositide 3-kinase (PI3K) enzyme and elucidating its role in cancer development. His research has led to the development of personalized cancer therapies targeting the PI3K signaling pathway.
Dr. Lucile Adams-Campbell is recognized for her scientific work in cancer epidemiology and health disparities, as well as her dedication to mentoring minority researchers. She will receive the AACR-MICR Jane Cooke Wright Lectureship at the AACR Annual Meeting 2015.
A lack of disclosure and elevated cancer risk are experienced by the LGBTQI community due to reduced access to healthcare and insurance. Researchers suggest training staff in LGBTQI competencies and collecting gender identity and sexual orientation data to improve patient care.
Dr. Vakoc's work reveals an essential connection between epigenetic regulation and oncogenesis, leading to potential new therapeutic approaches for leukemias and other cancers. He will present his lecture at the AACR Annual Meeting 2015.
The National Cancer Institute has renewed its grant to Norris Cotton Cancer Center, solidifying its status as a Comprehensive Cancer Center. The center offers top-notch patient care, cutting-edge research, and innovative treatments.
Dr. William Hahn receives the 39th annual AACR-Rosenthal Memorial Award for his seminal work on cancer initiation, maintenance, and progression. His research provides a foundation for novel therapeutic approaches now being tested in the clinic.
Low is being recognized for his pioneering development of low molecular weight ligands to deliver attached therapeutic and imaging agents selectively into pathologic cells such as cancer cells. This targeted therapeutic approach improves potency and reduces toxicity.
The Global Cancer Project Map is an online resource connecting the global cancer community, enabling access to cancer projects and expertise. The map covers a range of projects, from prevention to palliative care, and aims to reduce health disparities and strengthen human capital in underserved areas.
A blood test identified patients with advanced colorectal cancer who could benefit from a more intensive chemotherapy regimen, reducing hair loss and other side effects. The study found that patients with higher counts of circulating tumour cells in their blood responded better to treatment.
A new study found that cancer patients have variable knowledge about imaging tests, with most wanting basic education about radiation use and understanding how tests differ. Patients also desired information on potential long-term risks and participation in decision-making about medical imaging.
A breakthrough discovery by Queen's University researcher Madhuri Koti has identified biomarkers that can predict the success of chemotherapy in ovarian cancer patients. This finding holds promise for improving treatment options and increasing patient survival rates.
A new study from Brigham and Women's Hospital found that Asian-Americans diagnosed with cancer have significantly lower cancer-specific mortality rates compared to non-Hispanic white patients. The study analyzed data from over 2.5 million patients and broke down the population into eight subgroups, revealing variations in survival rate...
A new study evaluates currently available screening tools for senior cancer patients taking too many medications. It found that a more comprehensive assessment and monitoring plan is needed to improve treatment outcomes.
Researchers developed a non-invasive method to screen for kidney cancer by measuring protein biomarkers in urine, achieving over 95% accuracy. The findings suggest the potential for an easy-to-use screening test, similar to mammograms or colonoscopies, to identify patients with kidney cancer at early stages.
A study published in JAMA found significant discrepancies in diagnoses of atypia and DCIS, highlighting the need for women to seek second opinions. The study involved 115 pathologists and 6,900 breast biopsy interpretations, revealing a concordance rate of 75.3% for invasive carcinoma but only 48% for atypia.
A study by NCCS reveals a new attenuated-dose regimen of sunitinib improves patient quality of life and reduces treatment costs for Asian patients with metastatic renal cell carcinoma. The median overall survival rate increased to 27.4 months, reducing toxicities by 30% compared to the conventional dosing.
A new international study has found a small subset of patients with adrenal cancer respond significantly to the investigational drug linsitinib, paving the way for personalized treatment options. The researchers plan to analyze DNA collected from the study to identify possible markers for response.
Researchers at Georgetown University Medical Center have discovered a cellular pathway that controls organ size, which is also related to cancer cell behavior. High-density cells activated the 'Hippo' molecular pathway, while low-density cells did not engage with it, leading to differences in invasion and growth.
Two new studies present striking findings on depression's influence on cardiovascular health, with depressed patients facing nearly double the risk of dying from heart disease. Additionally, survivors of heart attacks are found to be at higher risk for certain cancers, including lung and bladder cancer.
A genetically engineered immunotoxin called DT2219 has shown safety and clinical effectiveness in a phase I trial for patients with relapsed/refractory B-cell malignancies. Two patients achieved durable objective responses, highlighting the potential of this new treatment approach.
The NCCN Clinical Practice Guidelines in Oncology provide evidence-based recommendations for smoking cessation in patients with cancer. Combining pharmacologic therapy and counseling is the most effective approach, leading to improved cancer treatment effectiveness and decreased recurrence.
Researchers identified germline TP53 gene mutations in 1.3% of patients with early-onset colorectal cancer, comparable to the proportion attributed to APC gene mutations. The findings highlight the need for clinicians to counsel patients undergoing TP53 testing as part of multigene risk assessment.
Patients treated at high-volume facilities for stage III non-small cell lung cancer (NSCLC) have longer overall survival when receiving definitive concurrent chemotherapy and radiation therapy. Studies show improved outcomes for patients treated at these centers, regardless of academic or community status.
Researchers discovered a molecular cause for parvovirus selectivity in cancer cells, revealing the PKCη/Rdx-driven phosphorylation of PDK1. This biomarker predicts therapy effectiveness and identifies cancer cells independent of growth factors.
A new study has identified a group of molecules in prostate-cancer cells that can help distinguish which patients should be treated with radiation therapy if rising PSA levels indicate tumor recurrence. MicroRNA patterns, including miR-4516 and miR-601, may predict patient response to radiation therapy.
A phase II study shows patients with high-risk low-grade gliomas have a 73% three-year overall survival rate when treated with radiation and temozolomide, compared to 54% for historical controls. The findings suggest combining chemotherapy with radiation is the best treatment for these rare tumors.
A family history of prostate cancer in first-degree relatives increases breast cancer risk by 14%, according to a study of 78,171 women. Women with both breast and prostate cancer histories face an almost 2-fold increase in breast cancer risk
Researchers at CWRU found that African-American cancer patients with depression often experience different symptoms than white patients, including irritability and social isolation. These findings suggest that culturally sensitive depression measures are needed to accurately diagnose and treat black cancer patients.
A phase 2 clinical trial found that sunitinib significantly improved progression-free survival in patients with advanced differentiated thyroid cancer. The study showed that 83% of patients benefited from treatment, with either tumor shrinkage or slowed disease progression.
Researchers found that fast food companies fail to promote healthy menu items in their kid's ads, while prioritizing toy premiums. Children recalled toys more than 70% of the time, but noticed food less than half of the time.
A new study identified older white males with advanced bladder cancer as a high-risk group for suicide. Researchers found that these patients have a higher suicide risk compared to those with other genitourinary cancers.
Researchers found that patients who received chemotherapy after bladder cancer surgery had improved overall survival rates compared to those who underwent surgery alone. The study analyzed over 5,600 patients and demonstrated a significant reduction in mortality risk.